Sometimes, an anxiety is so great that it obscures all the good things going on at once. Such is the case with stocks of pharmaceutical giants
AbbVie
The owner of the blockbuster drug Humira faces patent expiration.
Humira is an immunosuppressive drug that has raked in nearly $200 billion in sales since its approval in 2002. AbbVie (ticker: ABBV) has fought fiercely to extend the exclusivity of Humira, the drug treats conditions ranging from rheumatoid arthritis to Crohn’s disease, but it has lost patent protection in Europe and faces increasing competition from biosimilars in the US, which began from next year.
